Compare CVR & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVR | BRTX |
|---|---|---|
| Founded | 1920 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 9.3M |
| IPO Year | 1995 | 2015 |
| Metric | CVR | BRTX |
|---|---|---|
| Price | $13.57 | $0.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 7.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ 66.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,986,627.00 | $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.15 | $0.19 |
| 52 Week High | $15.00 | $2.10 |
| Indicator | CVR | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 35.70 |
| Support Level | $13.32 | $0.19 |
| Resistance Level | $14.47 | $1.18 |
| Average True Range (ATR) | 0.51 | 0.03 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 18.29 | 97.50 |
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.